Janssen submits sBLA to FDA for NSCLC combination therapy
The Janssen has submitted a sBLA to the US FDA for RYBREVANT plus chemotherapy for non-small cell lung cancer (NSCLC).
The Janssen has submitted a sBLA to the US FDA for RYBREVANT plus chemotherapy for non-small cell lung cancer (NSCLC).
What's Your Reaction?
